...
首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Formulation and In-vitro evaluation of Orodispersible tablets of Telmisartan
【24h】

Formulation and In-vitro evaluation of Orodispersible tablets of Telmisartan

机译:替米沙坦口腔分散片的配制及体外评价

获取原文
           

摘要

Orodispersible dosage forms are used for accurate dosing, enhanced bioavailability, rapid action, patient compliance, ease of administration, enhanced palatability. Telmisartan is an antihypertensive drug which belongs to the class of Angiotensin Receptor ΙΙ antagonist. It is a poorly soluble drug (BCS class-II) and the rate of absorption is limited by the dissolution rate. The reported bioavailability of drug is about 42%. In the present study an attempt was made to develop Oral dispersible tablets of Telmisartan formulated with super disintegrating agent with superior dissolution properties. The aim is to formulate various batches of oral disintegrating tablets of Telmisartan by using different superdisintegrants such as Indion 414, Indion 234 and Kyron T 314 with different concentrations individually by using different excipients like Mannitol, magnesium stearate and aspartame. Formulations of P1 to P13 are formulated with different superdisintegrants by wet granulation technique. The tablets were evaluated for the pre-compression parameters such as bulk density, compressibility, angle of repose etc. and post compression parameters like hardness, weight variation, friability, disintegration time and in-vitro dissolution profiles. Drug content for all formulation batches i.e. P1-P13 was found to be in the range of 99.76%-102.23%. Based on the evaluation of all parameters, the formulation P5 were found to be best on the basis of following crucial factors like hardness, drug content, disintegration time (14.4 sec) and wetting time.
机译:口腔分散剂型用于精确剂量,增强的生物利用度,快速作用,患者依从性,易于给药,适口性。替米沙坦是一种降压药,属于血管紧张素受体II拮抗剂。它是一种难溶药物(BCS II类),吸收速率受溶出速率限制。报道的药物生物利用度约为42%。在本研究中,尝试开发由具有优异溶解特性的超级崩解剂配制的替米沙坦口服分散片。目的是通过使用甘露醇,硬脂酸镁和阿斯巴甜等不同的赋形剂,分别使用不同浓度的Indion 414,Indion 234和Kyron T 314等不同的超崩解剂,配制出不同批次的替米沙坦口腔崩解片。通过湿法制粒技术,用不同的超崩解剂配制P1至P13的制剂。评价片剂的压缩前参数,例如堆积密度,可压缩性,休止角等,以及压缩后参数,例如硬度,重量变化,脆性,崩解时间和体外溶出曲线。发现所有制剂批次即P1-P13的药物含量在99.76%-102.23%的范围内。根据所有参数的评估,基于以下关键因素,例如硬度,药物含量,崩解时间(14.4秒)和润湿时间,发现配方P5最佳。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号